TC
ESPR

TFS Capital’s Esperion Therapeutics ESPR Stock Holding History

TFS Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-26,510
Closed -$262K – 809
2016
Q2 		$262K Buy
26,510
+15,402
+139% +$255K 0.05% 647
2016
Q1 		$188K Sell
11,108
-11,017
-50% -$177K 0.03% 784
2015
Q4 		$493K Buy
+22,125
New +$558K 0.05% 415
2014
Q1 		– Sell
-23,654
Closed -$325K – 1407
2013
Q4 		$325K Sell
23,654
-12,675
-35% -$184K 0.02% 1050
2013
Q3 		$685K Buy
+36,329
New +$610K 0.03% 727

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TFS Capital's ESPR Position: Q3 2016 in Review

TFS Capital sold out of Esperion Therapeutics (ESPR) in Q3 2016, closing a stake of 26,510 shares — an estimated $262K sold.

TFS Capital first reported a position in ESPR in Q3 2013 and held it in 5 quarters. The position peaked at $685K in Q3 2013. 102 funds tracked by Wall St. Rank hold ESPR as of Q3 2016.

  • TFS Capital reported no remaining Esperion Therapeutics position as of Q3 2016 after selling out during the quarter.
  • TFS Capital sold 26,510 Esperion Therapeutics shares in Q3 2016, an estimated $262K.
  • TFS Capital first reported a position in Esperion Therapeutics in Q3 2013 and held it in 5 quarters.
  • TFS Capital's Esperion Therapeutics position peaked at $685K in Q3 2013.
  • 102 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.